205 related articles for article (PubMed ID: 14711931)
1. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.
Avlani V; May LT; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2004 Mar; 308(3):1062-72. PubMed ID: 14711931
[TBL] [Abstract][Full Text] [Related]
2. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
[TBL] [Abstract][Full Text] [Related]
3. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K
Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174
[TBL] [Abstract][Full Text] [Related]
4. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors.
Krejcí A; Tucek S
Mol Pharmacol; 2001 Oct; 60(4):761-7. PubMed ID: 11562438
[TBL] [Abstract][Full Text] [Related]
5. Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators.
May LT; Lin Y; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2005 Jan; 312(1):382-90. PubMed ID: 15333678
[TBL] [Abstract][Full Text] [Related]
6. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
Lanzafame AA; Sexton PM; Christopoulos A
Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
[TBL] [Abstract][Full Text] [Related]
7. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
[TBL] [Abstract][Full Text] [Related]
8. Three allosteric modulators act at a common site, distinct from that of competitive antagonists, at muscarinic acetylcholine M2 receptors.
Lanzafame A; Christopoulos A; Mitchelson F
J Pharmacol Exp Ther; 1997 Jul; 282(1):278-85. PubMed ID: 9223565
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the interaction of a putative allosteric modulator, N-(2,3-diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) methanamine hydrobromide (SCH-202676), with M1 muscarinic acetylcholine receptors.
Lanzafame A; Christopoulos A
J Pharmacol Exp Ther; 2004 Mar; 308(3):830-7. PubMed ID: 14617684
[TBL] [Abstract][Full Text] [Related]
10. New insight into active muscarinic receptors with the novel radioagonist [³H]iperoxo.
Schrage R; Holze J; Klöckner J; Balkow A; Klause AS; Schmitz AL; De Amici M; Kostenis E; Tränkle C; Holzgrabe U; Mohr K
Biochem Pharmacol; 2014 Aug; 90(3):307-19. PubMed ID: 24863257
[TBL] [Abstract][Full Text] [Related]
11. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
[TBL] [Abstract][Full Text] [Related]
12. Testing the specificity of allosteric modulators of muscarinic receptors in phylogenetically closely related histamine H1-receptors.
Franken C; Tränkle C; Mohr K
Naunyn Schmiedebergs Arch Pharmacol; 2000 Feb; 361(2):107-12. PubMed ID: 10685864
[TBL] [Abstract][Full Text] [Related]
13. Competition between positive and negative allosteric effectors on muscarinic receptors.
Proska J; Tucek S
Mol Pharmacol; 1995 Oct; 48(4):696-702. PubMed ID: 7476896
[TBL] [Abstract][Full Text] [Related]
14. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites.
Schober DA; Croy CH; Xiao H; Christopoulos A; Felder CC
Mol Pharmacol; 2014 Jul; 86(1):116-23. PubMed ID: 24807966
[TBL] [Abstract][Full Text] [Related]
15. Two-state models and the analysis of the allosteric effect of gallamine at the M2 muscarinic receptor.
Ehlert FJ; Griffin MT
J Pharmacol Exp Ther; 2008 Jun; 325(3):1039-60. PubMed ID: 18305010
[TBL] [Abstract][Full Text] [Related]
16. Modes of allosteric interactions with free and [3H]N-methylscopolamine-occupied muscarinic M2 receptors as deduced from buffer-dependent potency shifts.
Schröter A; Tränkle C; Mohr K
Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):512-9. PubMed ID: 11138843
[TBL] [Abstract][Full Text] [Related]
17. Allosteric binding sites on muscarinic acetylcholine receptors.
Wess J
Mol Pharmacol; 2005 Dec; 68(6):1506-9. PubMed ID: 16183853
[TBL] [Abstract][Full Text] [Related]
18. Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors.
Cembala TM; Forde SC; Appadu BL; Lambert DG
Eur J Pharmacol; 2007 Aug; 569(1-2):37-40. PubMed ID: 17588565
[TBL] [Abstract][Full Text] [Related]
19. Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine M(2) receptors.
Tränkle C; Weyand O; Schröter A; Mohr K
Mol Pharmacol; 1999 Nov; 56(5):962-5. PubMed ID: 10531401
[TBL] [Abstract][Full Text] [Related]
20. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist.
Langmead CJ; Fry VA; Forbes IT; Branch CL; Christopoulos A; Wood MD; Herdon HJ
Mol Pharmacol; 2006 Jan; 69(1):236-46. PubMed ID: 16207821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
